EPS for InVivo Therapeutics Holdings Corp. (NVIV) Expected At $-0.16; Axis Capital Holdings LTD Has 1.16 Sentiment

February 16, 2018 - By Adrian Mccoy

AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products worldwide. The company has market cap of $4.25 billion. It operates through two divisions, Insurance and Reinsurance. It currently has negative earnings. The Insurance segment offers property insurance for commercial buildings, residential premises, construction projects, and onshore energy installations; marine insurance covering offshore energy, cargo, liability, recreational marine, fine art, specie, hull, and war; and terrorism, aviation, credit and political risk, and liability insurance.

Analysts expect InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) to report $-0.16 EPS on March, 9.They anticipate $0.05 EPS change or 23.81% from last quarter’s $-0.21 EPS. After having $-0.28 EPS previously, InVivo Therapeutics Holdings Corp.’s analysts see -42.86% EPS growth. The stock decreased 1.69% or $0.01 during the last trading session, reaching $0.51. About 36,114 shares traded. InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) has declined 65.27% since February 16, 2017 and is downtrending. It has underperformed by 81.97% the S&P500.

The stock increased 1.09% or $0.55 during the last trading session, reaching $51.06. About 68,151 shares traded. AXIS Capital Holdings Limited (AXS) has risen 17.55% since February 16, 2017 and is uptrending. It has outperformed by 0.85% the S&P500.

Vulcan Value Partners Llc holds 3.28% of its portfolio in AXIS Capital Holdings Limited for 6.69 million shares. New Vernon Investment Management Llc owns 34,250 shares or 2.18% of their US portfolio. Moreover, Nine Chapters Capital Management Llc has 1.57% invested in the company for 12,400 shares. The New York-based Pzena Investment Management Llc has invested 1.39% in the stock. General American Investors Co Inc, a New York-based fund reported 245,000 shares.

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company has market cap of $17.52 million. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: